Trillium Reports 2015 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- S&P 500, Nasdaq climb as AI-linked stocks recover ahead of earnings
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Oil slips from five-month highs with Hormuz crossings, Russian sanctions waiver in focus
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
- Brazil's Bolsonaro, Lula spar in first debate as personal attacks fly
- Cerebras Systems falls as TD Cowen cuts price target
- S&P 500, Nasdaq climb as AI-linked stocks recover ahead of earnings
- Glass House Brands posts Q3 revenue of $56.8M, board member exits
- Nvidia wins CPU business from Modal, previously exclusive to AMD and Intel
Leerink Partners Remains Bullish as Trillium Therapeutics (TRIL) Continues TTI-621 Development
March 10, 2016 7:48 AM ESTLeerink Partners maintained an Outperform rating on Trillium Therapeutics (NASDAQ: TRIL) price target of $20.00 (from $29.00). Earlier this year TRIL initiated dosing in its Ph I where TTI-621 will be evaluated as a monotherapy in patients with relapsed/refractory hematological malignancies. While TRIL has broadened its portfolio with the recent acquisition of... More



